Search

Your search keyword '"Adank MA"' showing total 93 results

Search Constraints

Start Over You searched for: Author "Adank MA" Remove constraint Author: "Adank MA"
93 results on '"Adank MA"'

Search Results

1. Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases

2. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

3. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

4. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

5. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

6. Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.

7. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

8. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

9. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

10. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

11. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

12. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

13. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts

14. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

15. Prediction and clinical utility of a contralateral breast cancer risk model

16. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

17. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

18. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

19. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

20. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

21. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

22. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

23. Performance of BRCA1/2 mutation prediction models in male breast cancer patients

24. Association analysis identifies 65 new breast cancer risk loci

25. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

26. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

27. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

28. MicroRNA Related Polymorphisms and Breast Cancer Risk

29. MicroRNA Related Polymorphisms and Breast Cancer Risk

30. Association analysis identifies 65 new breast cancer risk loci

31. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

32. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

33. Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

34. Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.

35. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.

36. Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

37. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families.

38. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

39. Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases.

40. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.

41. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women.

42. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.

43. Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.

44. Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.

45. Breast cancer risks associated with missense variants in breast cancer susceptibility genes.

46. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

47. Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

48. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

49. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

50. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.

Catalog

Books, media, physical & digital resources